William Blair research analyst Max Smock was quoted in biopharma trade magazine BioSpace recently, discussing the “headwinds” that faced contract manufacturing and development organizations (CMDOs) in 2023.
“For all these companies, just transitioning away from COVID has been the thing that it’s been difficult,” Smock cited in the publication as one of the issues facing CMDOs.